{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-211584","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.841032+00:00","generated_at":"2026-05-31T06:38:05.661265+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis","bullets":["Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.","Independent Data Monitoring Committee recommended continuing PEAK study after pre-planned interim futility analysis.","SUMMIT trial in NonAdvSM now expects to complete enrollment in Q1 2025, three months earlier than projected.","Darara Dibabu appointed VP of Marketing; granted inducement award of 100,000 stock options at $10.74 per share.","Bezuclastinib combination with sunitinib for second-line GIST is primary focus of registration-directed trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-211584","json":"https://secwatch.observer/filing/0001193125-24-211584.json","markdown":"https://secwatch.observer/filing/0001193125-24-211584.md","text":"https://secwatch.observer/filing/0001193125-24-211584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524211584/0001193125-24-211584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524211584/d873439d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:38:05.661265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}